drugset
drugset / Trial / NCT05599256

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

NCT05599256 ↗

Phase 2 Unknown 40 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelPrevention

Summary

To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of child patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model.

Timeline

Start
2023-02-09
Primary completion
2024-10-07
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 2.5 mg Oral
Subject Ruxolitinib Small molecule 5 mg Oral

Indications

acute graft versus host disease